Journal of Clinical Epidemiology
Volume 54, Issue 5 , Pages 518-524 , May 2001

Evaluating adverse cardiovascular effects of drug treatment for benign prostatic hyperplasia (BPH) Methodological considerations

  • P.C Souverein

      Affiliations

    • Department of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences (UIPS), PO Box 80082, 3508 TB Utrecht, The Netherlands
    • Corresponding Author InformationCorresponding author. Tel.: +31-30-253 7324; fax: +31-30-253 9166.(P.C. Souverein)
    • ,
  • R.M.C Herings

      Affiliations

    • Department of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences (UIPS), PO Box 80082, 3508 TB Utrecht, The Netherlands
    • ,
  • J.J.M.C.H De la Rosette

      Affiliations

    • Department of Urology, University Hospital Nijmegen, PO Box 9101, 6500 HB Nijmegen, The Netherlands
    • ,
  • A.J.Man in ‘t Veld

      Affiliations

    • Department of Internal Medicine, University Hospital Dijkzigt, PO Box 1738, 3000 DR Rotterdam, The Netherlands
    • ,
  • R.D.T Farmer

      Affiliations

    • European Institute of Health and Medical Sciences, University of Surrey, Stirling House, Stirling Road, Guildford, Surrey 942 SRF, UK
    • ,
  • H.G.M Leufkens

      Affiliations

    • Department of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences (UIPS), PO Box 80082, 3508 TB Utrecht, The Netherlands

Received 1 December 1999 ,Revised 30 June 2000 ,Accepted 21 August 2000.

References 

  1. Suissa S, Ernst P, Boivin JF, Horwitz RI, Habbick B, Cockroft D, et al. A cohort analysis of excess mortality in asthma and the use of inhaled beta-agonists. Am J Respir Crit Care Med. 1994;149(3):604–610
  2. Psaty BM, Heckbert SR, Koepsell TD, Siscovick DS, Raghunathan TE, Weiss NS, et al.  The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA. 1995;274(8):620–625
  3. Spitzer WO, Lewis MA, Heinemann LA, Thorogood M, MacRae KD. Third generation oral contraceptives and risk of venous thromboembolic disorders (an international case-control study). Transnational Research Group on Oral Contraceptives and the Health of Young Women, BMJ. 1996;312(7023):83–88
  4. Rosenberg L, Rao RS, Palmer JR, Strom BL, Stolley PD, Zauber AG, et al. Calcium channel blockers and the risk of cancer. JAMA. 1998;279(13):1000–1004
  5. Grobbee DE, Hoes AW. Confounding and indication for treatment in evaluation of drug treatment for hypertension. BMJ. 1997;315(7116):1151–1154
  6. Petri H, Urquhart J. Channeling bias in the interpretation of drug effects. Stat Med. 1991;10(4):577–581
  7. Bloemenkamp KW, Rosendaal FR, Buller HR, Helmerhorst FM, Colly LP, Vandenbroucke JP. Risk of venous thrombosis with use of current low-dose oral contraceptives is not explained by diagnostic suspicion and referral bias. Arch Intern Med. 1999;159(1):65–70
  8. Farmer RD, Lawrenson RA, Hambleton IR. Oral contraceptive switching patterns in the United Kingdom (an important potential confounding variable in studies of venous thromboembolism). Eur J Contracept Reprod Health Care. 1996;1(1):31–37
  9. Garbe E, Boivin JF, LeLorier J, Suissa S. Selection of controls in database case-control studies (glucocorticoids and the risk of glaucoma). J Clin Epidemiol. 1998;51(2):129–135
  10. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol. 1984;132(3):474–479
  11. Abrams P, Schulman CC, Vaage S. Tamsulosin, a selective alpha 1c-adrenoceptor antagonist (a randomized, controlled trial in patients with benign prostatic “obstruction” (symptomatic BPH)). The European Tamsulosin Study Group. Br J Urol. 1995;76(3):325–336
  12. Holtgrewe HL. Current trends in management of men with lower urinary tract symptoms and benign prostatic hyperplasia. Urology. 1998;51(Suppl 4A):1–7
  13. Chapple CR. Pharmacotherapy for benign prostatic hyperplasia—the potential for alpha 1-adrenoceptor subtype-specific blockade. Br J Urol. 1998;81(Suppl 1):34–47
  14. Narayan P, Tewari A. Overview of alpha-blocker therapy for benign prostatic hyperplasia. Urology. 1998;51(Suppl 4A):38–45
  15. Roehrborn CG. Meta-analysis of randomized clinical trials of finasteride. Urology. 1998;51(Suppl 4A):46–49
  16. Man In ‘tVeld AJ, van der Camme TJ, van Loon K . Drug treatment of hypertension in the elderly (the role of alpha-adrenoceptor blockade). Br J Urol. 1998;81(Suppl 1):21–25
  17. Chapple CR. Selective alpha 1-adrenoceptor antagonists in benign prostatic hyperplasia (rationale and clinical experience). Eur Urol. 1996;29(2):129–144
  18. Pool JL. Doxazosin (a new approach to hypertension and benign prostatic hyperplasia). Br J Clin Pract. 1996;50(3):154–163
  19. Boyle P, Napalkov P. The epidemiology of benign prostatic hyperplasia and observations on concomitant hypertension. Scand J Urol Nephrol Suppl. 1995;168:7–12
  20. Ottervanger JP, Wilson JH, Stricker BH. Drug-induced chest pain and myocardial infarction. Reports to a national centre and review of the literature. Eur J Clin Pharmacol. 1997;53(2):105–110
  21. Herings RM, de Boer A, Stricker BH, Leufkens HG, Porsius A. Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme. Lancet. 1995;345(8959):1195–1198
  22. Herings RM, Stricker BH, de Boer A, Bakker A, Sturmans F. Benzodiazepines and the risk of falling leading to femur fractures. Dosage more important than elimination half-life. Arch Intern Med. 1995;155(16):1801–1807
  23. Leufkens HGM, Urquhart J. Automated record linkage and other approaches to pharmacoepidemiology in The Netherlands. In:  Strom BL editors. Pharmacoepidemiology. 2nd ed. Chichester: John Wiley & Sons; 1994;p. 231–244
  24. Von Korff M, Wagner EH, Saunders K. A chronic disease score from automated pharmacy data. J Clin Epidemiol. 1992;45(2):197–203
  25. Merlo J, Ranstam J, Liedholm H, Hedblad B, Lindberg G, Lindblad U, et al.  Incidence of myocardial infarction in elderly men being treated with antihypertensive drugs (population based cohort study). BMJ. 1996;313:457–461
  26. Stoevelaar HJ, Van de Beek C, Casparie AF, McDonnell J, Nijs HG. Treatment choice for benign prostatic hyperplasia (a matter of urologist preference?). J Urol. 1999;161(1):133–138
  27. Wolfs GG, Knottnerus JA, Janknegt RA. Prevalence and detection of micturition problems among 2,734 elderly men. J Urol. 1994;152(5):1467–1470
  28. Wille-Gussenhoven MJ, de Bock GH, de Beer-Biujs MJ, Burgers SM, Buurman CM, Evenaar M, et al. Prostate symptoms in general practice (seriousness and inconvenience). Scand J Prim Health Care. 1997;15(1):39–42
  29. Bosch JL, Hop WC, Kirkels WJ, Schroder FH. Natural history of benign prostatic hyperplasia (appropriate case definition and estimation of its prevalence in the community). Urology. 1995;46(3 Suppl A):34–40
  30. Lukacs B, Leplege A, Thibault P, Jardin A. Prospective study of men with clinical benign prostatic hyperplasia treated with alfuzosin by general practitioners (1-year results). Urology. 1996;48(5):731–740
  31. Michel MC, Mehlburger L, Bressel HU, Schumacher H, Schafers RF, Goepel M. Tamsulosin treatment of 19,365 patients with lower urinary tract symptoms (does co-morbidity alter tolerability?). J Urol. 1998;160(3):784–791

PII: S0895-4356(00)00327-9

Journal of Clinical Epidemiology
Volume 54, Issue 5 , Pages 518-524 , May 2001

Article Tools

* Image Usage & Resolution